All In MedTech

Device Trial Radar · NCT06911632

Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension

MOMENTOUS Study (iMpact Of an Ecg ai ModEl oN The Diagnosis Of pUlmonary hypertenSion)

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 900 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

900

Planned (sponsor's estimate)

Start

Jul 23, 2025

Primary completion

May 2028

Study completion Jul 2028

Sponsor

Lead sponsor
Tempus AINot on our public-company list
Sponsor type
Industry
Collaborators
United Therapeutics
First posted
Apr 4, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

MOMENTOUS is a multi-center, randomized study to prospectively evaluate the performance of an ECG-based AI device to predict whether participants with interstitial lung disease (ILD) are at high risk of undiagnosed pulmonary hypertension.

Conditions

  • Pulmonary Hypertension
  • Interstitial Lung Disease (ILD)

Interventions

  • ECG-based AI Device - Results Returned to InvestigatorDevice

    An ECG-based AI device that predicts undiagnosed PH using data from a 12-lead ECG. Device results will be returned to the Investigators.

  • Echocardiogram and Right Heart CatheterizationProcedure

    Echocardiogram- an ultrasound study of the heart and Right Heart Catheterization- a procedure to measure pressures in the heart

  • ECG-based AI Device - Results Not Returned to InvestigatorDevice

    An ECG-based AI device that predicts undiagnosed PH using data from a 12-lead ECG. Device results will not be returned to the Investigators.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants receiving a new diagnosis of PH within the High risk Device group compared to the High risk Control group.Time frame: Through study completion, approximately 6 months

Locations

41 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • Banner University Medical Center

    Phoenix, Arizona · Recruiting

  • Dignity Health - St. Joseph's Hospital and Medical Center-Norton Thoracic Institute

    Phoenix, Arizona · Recruiting

38 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.